Research Frontier
Copyright ©2009 Baishideng. All rights reserved.
World J Hepatol. Oct 31, 2009; 1(1): 8-16
Published online Oct 31, 2009. doi: 10.4254/wjh.v1.i1.8
Future perspectives on the treatment of hepatocellular carcinoma with cisplatin
Toru Ishikawa
Toru Ishikawa, Department of Gastroenterology and Hepatology, Saiseikai Niigata Second Hospital, Niigata 950-1104, Japan
Author contributions: Ishikawa T solely contributed to this paper.
Correspondence to: Toru Ishikawa, MD, Department of Gastroenterology and Hepatology, Saiseikai Niigata Second Hospital, Teraji 280-7, Niigata 950-1104, Japan.
Telephone: +81-25-2336161 Fax: +81-25-2338880
Received: August 4, 2009
Revised: September 9, 2009
Accepted: September 16, 2009
Published online: October 31, 2009

Hepatocellular carcinoma (HCC) is the commonest primary liver malignancy. Its incidence is increasing worldwide. Surgery, including transplantation resection, is currently the most effective treatment for HCC. However, recurrence rates are high and long-term survival is poor. Conventional cytotoxic chemotherapy has not provided clinical benefit or prolonged survival for patients with advanced HCC. Cisplatin (CDDP) is a key drug for the standard regimens of various cancers in the respiratory, digestive and genitourinary organs. Recently, several encouraging results have been shown in using CDDP in the treatment of advanced HCC patients. This review examines current knowledge regarding the chemotherapeutic potential of CDDP.

Keywords: Hepatocellular carcinoma, Hepatic arterial infusion, Cisplatin